Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 8/20 | 0.54 |
| ▸ | CDK1 | P06493 | 8/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 0.54 |
| ▸ | GSK3B | P49841 | 7/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31721163 | 0.90 | LMNA (1.00) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL4156981 | 0.90 | LMNA (0.94) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL2360729 | 0.90 | LMNA (1.00) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL5263677 | 0.80 | MAPT (0.69) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL29855719 | 0.80 | MAPT (0.69) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL1003250 | 0.78 | LMNA (0.78) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL29452862 | 0.78 | LMNA (0.78) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL20602011 | 0.77 | LMNA (0.59) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL2360271 | 0.77 | MAPT (0.59) | LMNAALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL5918264 | 0.77 | HSD17B10 (0.79) | LMNAALDH1A1MAPTMAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025231227-A1 | NEW COMPOUNDS FOR MEDICAL USE | MOGLING BIO INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-12-19 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2020-10-15 | — | — | US | disclosed |
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| EP-1658068-B1 | NOVEL CYCLOALKYL[B] CONDENSED INDOLES | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | SMITHKLINE BEECHAM CORPORATION | 2006-12-14 | — | — | US | disclosed |
| EP-1658068-A1 | NOVEL CYCLOALKYL'B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005023245-A1 | NOVEL CYCLOALKYL’B! CONDENSED INDOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200325124-A1 | THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION | ABCB11, SLC47A1, SLC47A2 | LMNA 3829/4885ALDH1A1 1099/4885MAPT 4489/4885 |
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | LMNA 4279/4885ALDH1A1 1558/4885MAPT 1187/4885 |
| US-11845742-B2 | Therapeutic compounds and methods to treat infection | ABCB11, SLC47A1, SLC47A2 | LMNA 3829/4885ALDH1A1 1099/4885MAPT 4489/4885 |
| US-20060281804-A1 | Novel cycloalkyl'b! condensed indoles | BCCIP, TP53, TOP2B | LMNA 2198/4885ALDH1A1 3045/4885MAPT 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.